PureTech Health (PRTC) said Monday that a phase 2 clinical trial of its drug deupirfenidone as a treatment of patients with idiopathic pulmonary fibrosis reached its primary endpoint.
IPF is a rare, progressive, and often fatal lung disease with a median survival of two to five years.
In the 26-week trial, patients given 825 mg doses of the deupirfenidone three times a day saw lung function improve 50% greater than those treated with pirfenidone, the standard of care, the company said.
Both 825 mg and 550 mg doses of the drug were "generally well-tolerated" in the 257-patient trial, the company said.
PureTech said it will discuss the phase 2 results with regulatory authorities to map out a future path for approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.